Navigation Links
Researchers identify how a gene linked to both Alzheimer's disease and type 2 diabetes works
Date:7/18/2011

Researchers at Mount Sinai School of Medicine have identified how a gene for a protein that can cause Type 2 diabetes, also possibly kills nerve cells in the brain, thereby contributing to Alzheimer's disease.

The gene, called SorCS1, controls the generation of amyloid-beta (Abeta) in the brain. Abeta plays a key role in the development of Alzheimer's disease. The researchers previously linked SorCS1 to Alzheimer's disease and identified where the molecules lived in the cell, but not how they control Abeta. The new data were presented today at the Alzheimer's Association's Annual International Conference in Paris.

Sam Gandy, MD, PhD, the Mount Sinai Professor in Alzheimer's Disease Research, Professor of Neurology and Psychiatry, and Associate Director of the Alzheimer's Disease Research Center at Mount Sinai School of Medicine, led the research team with Rachel Lane, PhD, a postdoctoral researcher in Dr. Gandy's lab.

The researchers determined various "traffic patterns" in the cell for the amyloid precursor protein (APP) that makes Abeta and uncovered how much APP is converted into the toxic, and ultimately nerve-killing, Abeta. In some experiments Drs. Lane and Gandy altered the dose of the diabetes gene, SorCS1, and evaluated how that changed the "traffic pattern" that APP used to move around the cell and generate Abeta. In other experiments, Dr. Lane made small changes in the SorCS1 gene's and again saw dramatic changes in the "traffic pattern" of APP around the cell.

These data suggest that SorCS1 controls the movement of APP within the cell between areas where Abeta is readily made to areas where Abeta is not so easily made. In turn, the "traffic pattern" of influences the amount of Abeta being made by cells. The implication is that people with deficiencies in SorCS1 are at higher risk of developing Alzheimer's disease because their APP spends too much time in the region of the cell where APP is broken down to make the toxic Abeta.

"The great thing about studying SorCS1," said Dr. Gandy, "is that we already have entirely new ideas about how to treat both Alzheimer's disease and type 2 diabetes. Our hunch is that SorCS1 also controls how the insulin receptor moves around the cell, but we have not yet proven that," he said. "With both diseases reaching epidemic proportions, this discovery is encouraging news that brings us one step closer to developing treatments."


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. NYU researchers develop compound to block signaling of cancer-causing protein
2. Mayo researchers: Genetic mutation linked to Parkinsons disease
3. Researchers Closer to Developing Universal Meningitis B Vaccine
4. Novel Virus Jumped From Monkeys to Humans, Researchers Find
5. Dentists can identify people with undiagnosed diabetes, Columbia researchers show
6. UAB researchers present a study on the psychological adaptation of adopted children
7. Researchers identify key role of microRNAs in melanoma metastasis
8. A change of heart: Penn researchers reprogram brain cells to become heart cells
9. Researchers identify early biomarker for future atopy in asymptomatic children
10. Berkeley Lab researchers apply NMR/MRI to microfluidic chromatography
11. Leeds researchers test benefit of fish oil in bowel cancer spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a ... announced a new agreement as part of a long-term extension of their media partnership. ... the airing of some of the sport’s premier events exclusively on FloWrestling.com as well ...
(Date:1/16/2017)... ... January 16, 2017 , ... California Southern University has named Dr. ... CalSouthern’s Board of Trustees and as a core faculty member, teaching master’s and doctoral ... professor of psychology at Pepperdine University, where he earned his Doctor of Psychology degree ...
(Date:1/16/2017)... ... January 16, 2017 , ... Anybody who may be looking ... a new video released by Serenity Recovery, a holistic treatment center for addiction located ... channel, features footage and testimonials from patients and staff that visited the 2016 Recovery ...
(Date:1/16/2017)... ... 2017 , ... Specialty Technical Publishers (STP) and Specialty Technical ... (IAPC) EHS audit protocol for Singapore . Leading companies around the world ... obligations and rapidly collect, share, archive, and export audit findings in a cost ...
(Date:1/16/2017)... Hills, CA (PRWEB) , ... January 16, 2017 ... ... a manuscript in the Aesthetic Surgery Journal , the official journal of ... he conducted on lower eyelid retraction surgery. The procedure is designed to correct ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... OilPrice.com Market Commentary:  A little-known biotech company ... the planned upcoming release of a breakthrough technology that ... test that is affordable and accessible to the average ... today include:  Amgen Inc. (NASDAQ: AMGN ), ... Inc. (NASDAQ: CGIX ), Abbott Laboratories (NYSE: ...
(Date:1/17/2017)... Pa. , Jan. 17, 2017  Maureen ... Inc.(AMI) announces the addition of 6 senior sales ... the TubeClear® System.  These sales leaders were formerly ... acquired medical device company. Repeatedly recognized for their ... exceeding customer expectations and establishing relationships with key ...
(Date:1/17/2017)... Jan. 17, 2017  Tetra Discovery Partners today ... as Vice President, Clinical Operations. He joins ... Executive Director, Clinical Project Management. "Richard joins ... experience in global clinical research planning and execution, ... clinical operation build-outs and development partnerships," said ...
Breaking Medicine Technology: